Back to News
Market Impact: 0.35
Babesiosis Data Readout Today As 60 Degrees Pharmaceuticals Shares Climb
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
60 Degrees Pharmaceuticals shares rose about 18% as investors awaited an interim data release today from its Phase 2 study of tafenoquine in patients hospitalized with severe babesiosis. The article reports no study findings; the share move reflects anticipation of the update.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
SXTP0.20
More News
- Why Dangote’s Nigeria Refinery IPO Is Such a Big Deal for Africa
- A 32% beat, a +6% jump: the IT solutions name our models picked in July
- Nvidia Is on the Verge of a $6 Trillion Market Value
- Controversial $110 billion mega-merger of Paramount and Warner Bros. finally closes
- What Marvell's rosy long-term guidance means for our AI chip stocks
- GIC Private Ltd, Medline 10% owner, sells over $721m in shares